TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Travere Therapeutics, Inc.
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $4.72B
- P/E (TTM)
- –
- Dividend yield
- –
Travere Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 27 | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $161.35M | $124.49M | $126.61M | $113.15M | $94.84M | $75.86M | $73.55M | $61.00M | $52.18M | $39.98M | $39.92M | $33.93M | 95.1% | +70.1% |
| FILSPARI | $141.08M | $105.15M | $103.34M | $90.90M | $71.89M | $55.88M | $49.64M | $35.62M | $27.13M | $19.83M | $14.70M | $8.04M | 83.2% | +96.2% |
| Tiopronin products | $20.27M | $19.34M | $23.27M | $22.25M | $22.96M | $19.98M | $23.90M | $25.38M | $25.05M | $20.15M | $25.22M | $25.89M | 12.0% | -11.7% |
| License and collaboration revenue | $8.23M | $2.71M | $3.08M | $51.71M | $19.61M | $5.87M | $1.24M | $1.90M | $1.94M | $1.39M | $5.14M | $3.16M | 4.9% | -58.0% |
| Clinical Development Activity | – | – | – | – | – | – | – | – | – | – | $5.10M | $3.20M | – | – |
| Active Pharmaceutical Ingredient | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Travere Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.